Department of Medical Oncology, Hacettepe University Institute of Cancer, Hamamonu, 06100, Ankara, Turkey.
Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Cancer Chemother Pharmacol. 2019 Jun;83(6):1195-1196. doi: 10.1007/s00280-019-03810-9. Epub 2019 Mar 12.
Because of the rapid response to crizotinib, patients with ALK-positive locally advanced disease may become resectable with the use of neoadjuvant crizotinib. A 41-year-old never-smoking man who presented with asthma attack was found to have a suspicious lesion on chest X-ray after. Pathological examination was consistent with ALK(+), the signet-ring cell adenocarcinoma. Surgery was not performed because of mediastinal invasion of the mass. After 4 weeks of crizotinib treatment, a major response was achieved and the tumor became completely cavitary. Short-term neoadjuvant therapy with crizotinib for 4 weeks might be a promising therapy in locally advanced ALK-positive NSCLC and might provide a chance for resectability.
由于克唑替尼的快速反应，ALK 阳性局部晚期疾病的患者可能可以通过使用新辅助克唑替尼来进行可切除手术。一名 41 岁从不吸烟的男子因哮喘发作，胸部 X 射线检查发现可疑病变。病理检查结果与 ALK(+)、印戒细胞腺癌一致。由于肿块侵犯纵隔，未进行手术。克唑替尼治疗 4 周后，取得了显著缓解，肿瘤完全空洞化。4 周的短期新辅助克唑替尼治疗可能是局部晚期 ALK 阳性 NSCLC 的一种有前途的治疗方法，并可能为可切除性提供机会。
